1. Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo
- Author
-
David Michelson, R. Bruce Lydiard, Mark H. Pollack, Roy N. Tamura, Sharon L. Hoog, Rosalinda Tepner, Mark A. Demitrack, Gary D. Tollefson, and null the Fluoxetine Panic Disorder Study
- Subjects
Fluoxetine ,medicine.medical_specialty ,Hamilton Anxiety Rating Scale ,Panic disorder ,Panic ,medicine.disease ,behavioral disciplines and activities ,humanities ,Phobic disorder ,Psychiatry and Mental health ,Rating scale ,mental disorders ,medicine ,Clinical Global Impression ,medicine.symptom ,Psychology ,Psychiatry ,Anxiety disorder ,Clinical psychology ,medicine.drug - Abstract
Objective:Although panic attacks account for only a portion of the morbidity of panic disorder and panic attack frequency assessments are unreliable, studies of drug efficacy in panic disorder have generally used reduction in panic attack frequency as the primary measure of improvement. The authors studied the efficacy of fluoxetine treatment in panic disorder and measured the relative contributions of changes in symptoms to overall improvement.Method:Patients with a diagnosis of panic disorder (N=243) were randomly assigned to treatment with 10 or 20 mg/day of fluoxetine or placebo. Primary outcome measures were change in panic attack frequency and clinician-rated Clinical Global Impression improvement scores. Other assessments included a panic attack inventory, clinician-rated and patient-rated versions of the Panic and Phobic Disorder Change Scale, a phobia rating scale, the Hamilton Anxiety Rating Scale, the 21-item Hamilton Depression Rating Scale, and the Sheehan Disability Scale. Correlations were ...
- Published
- 1998
- Full Text
- View/download PDF